What is Transomic Technologies?
Transomic Technologies operates at the intersection of advanced molecular biology and pharmaceutical research, providing a comprehensive suite of lentiviral-based functional genomics tools. The company is a critical partner for researchers utilizing next-generation technologies, most notably CRISPR-Cas9, to drive discovery and therapeutic development. By offering specialized services ranging from the creation of knockout cell lines to complex CRISPR screening assays, Transomic Technologies enables major pharmaceutical entities to streamline their R&D pipelines.
The company's market position is defined by its technical proficiency in genomic manipulation and its ability to deliver custom, high-fidelity research solutions. As the demand for precision medicine and targeted genetic therapies continues to rise, Transomic Technologies remains a vital link in the supply chain for innovation, providing the essential tools required to decode biological complexity and translate findings into actionable medical insights.
How much funding has Transomic Technologies raised?
Transomic Technologies has raised a total of $375K across 1 funding round:
Private Equity
$375K
Private Equity (2022): $375K with participation from Immunotherapy
Key Investors in Transomic Technologies
Immunotherapy
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the body's immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases.
What's next for Transomic Technologies?
Looking ahead, the strategic deployment of the $375K investment will likely focus on scaling the company's proprietary delivery platforms and enhancing its service capacity for global pharmaceutical partners. Given the late-stage nature of this funding, the company is expected to prioritize operational efficiency and the expansion of its CRISPR-based screening capabilities to meet the increasing complexity of modern drug discovery. By deepening its integration into the pharmaceutical R&D ecosystem, Transomic Technologies is poised to capitalize on the growing reliance on functional genomics to solve critical challenges in oncology and infectious disease research. The firm's trajectory suggests a continued commitment to maintaining its status as a premier provider of genomic research tools, potentially exploring new frontiers in non-viral delivery mechanisms to further differentiate its service portfolio.
See full Transomic Technologies company page
